Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
The FDA is about to make weight-loss drugs a lot harder to get
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.
Hidden Dangers of Compounded Weight-Loss Drugs
A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often misleading users about FDA approval. Researchers identified over 70 websites with vague safety disclosures.
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia. But these drugs also come with risks that shouldn't be overlooked,
Study finds popular weight loss drugs may help with other health conditions
Obesity expert Dr. Naomi Parrella of Rush University joins Marie Saavedra to talk about the new study and the impact for patients.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer and dementia, a sweeping new study shows.
Researchers reveal benefits, risks linked to popular weight-loss drugs
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,
Hosted on MSN
6d
Nicotine pouches get FDA approval, with some calling them Gen Z's favorite weight loss hack
Little pouches of nicotine sold by the brand ZYN were given the green light for marketing this week through the U.S. Food and ...
12d
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
6d
Outgoing FDA chief flags online weight loss drug dangers
Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...
6d
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
4d
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
Arizona's Family on MSN
12d
Phoenix-area compounding pharmacies offer cheaper weight loss drugs
Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.
1d
Can Lexapro Cause Weight Loss? What to Know
If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Food and Drug Administration
Feedback